Skip to main content

Table 3 Medical therapya for inflammatory bowel disease within the first year of diagnosis

From: Epidemiology, validation, and clinical characteristics of inflammatory bowel disease: the ABIS birth cohort study

Therapy

Crohn's disease

N = 27

Ulcerative colitis

N = 27

Oral corticosteroids

 Yes

24 (89%)

15 (56%)

 No

1 (4%)

8 (30%)

 Missing data

2 (7%)

4 (15%)

Oral 5-ASA

 Yes

18 (67%)

17 (63%)

 No

7 (26%)

6 (22%)

 Missing data

2 (7%)

4 (15%)

Azathioprine

 Yes

21 (78%)

9 (33%)

 No

4 (15%)

14 (52%)

 Missing data

2 (7%)

4 (15%)

Biologics

 Yes

9 (33%)

1 (4%)

 No

16 (59%)

22 (81%)

 Missing data

2 (7%)

4 (15%)

  1. aData restricted to systemic medical therapy of 57 patients who had a validated (true) inflammatory bowel disease diagnosis on medical record review. Three patients with undefined inflammatory bowel disease (IBD) were not specifically reported in the table: three had oral corticosteroids, two with undefined IBD had 5-aminosalicylic acid (5-ASA), one had azathioprine and none of those three with undefined IBD had biologics
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us